Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 11 to 14 amino acid residues in defined sequence
Reexamination Certificate
1999-12-16
2002-08-20
Low, Christopher S. F. (Department: 1653)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
11 to 14 amino acid residues in defined sequence
C514S002600, C514S014800, C530S345000
Reexamination Certificate
active
06437092
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to conjugates of antinociceptive agents, notably opioids, and endogenous carriers, particularly to opioids and various blood components, particularly blood proteins.
BACKGROUND OF THE INVENTION
Antinociceptive agents comprise a large class of drugs that are used to alleviate pain. They include compounds such as steroids, analgesics, barbiturates and opioids.
The opioids comprise a large class of drugs, clinically used to relieve pain, and which include both plant-derived and synthetic alkaloids and peptides found indigenously in brains of mammals. The latter comprise three distinct families: beta-endorphin and other peptides derived from proopiomelanocortin, the enkephalins and the dynorphins. Opioids interact with neuronal cells and modulate physiological functions such as nociception. One of the physiological effects attributed to this class of compounds is analgesia.
While opioid drugs are used clinically to relieve pain their usefulness is limited by the tolerance and dependence that normally develops on chronic treatment. Opioid drugs such as morphine can be addictive and can have central mediated side effects such as respiratory and cardiac depressions and drowsiness. It would be desirable to develop therapeutic agents that could utilize the pain alleviating properties of the opioids without, or with lessened, central mediated side effects. It would also be desirable to be able to develop therapeutic agents which retain the positive properties of opioids and/or other antinociceptive agents for longer periods of time than is normally currently the case.
SUMMARY OF THE INVENTION
This invention relates to novel chemical reactive derivatives of antinociceptive agents, particularly opioids, which can react with available reactive functionalities on blood components to form covalent linkages, and in which the resulting covalently bound conjugates have antinociceptive activity.
As compared with the parent drugs the conjugated molecules have extended lifetimes in the bloodstream and are, therefore, capable of maintaining activity for extended periods of time as compared to the unconjugated parent drug, and of providing such activity with minimal or no centrally mediated side effects.
The invention also includes the conjugates of these drugs with blood components and methods for providing activity to a patient comprising administering to the bloodstream of a mammalian host the novel antinociceptive agent derivatives or the novel conjugates.
This invention relates to the use of the derivatives of this invention for the treatment of pain as well as to modify the immune response in patients.
This invention also relates to use of antibodies to locate and bind to such conjugates, for instance, to remove undesirable excesses of them from the host's blood stream.
REFERENCES:
patent: 4361553 (1982-11-01), Loh et al.
patent: 4462941 (1984-07-01), Lee et al.
patent: 5017689 (1991-05-01), Hruby et al.
patent: 5376662 (1994-12-01), Ockert et al.
patent: 5482930 (1996-01-01), Wei et al.
patent: 5612034 (1997-03-01), Pouletty et al.
patent: 5807827 (1998-09-01), Lee et al.
patent: 5945033 (1999-08-01), Yen
patent: WO 91/08220 (1991-06-01), None
patent: WO 93/25217 (1993-12-01), None
patent: WO 95/10302 (1995-04-01), None
patent: WO 96/06626 (1996-03-01), None
patent: WO 98/00171 (1998-01-01), None
patent: WO 99/24462 (1999-05-01), None
Filho, Pharm Sci 2 199-201, 1996.*
Correa, Pharm Sci 3, 67-71, 1997.*
Dooley, et al. Six Highly Active MU-Selective Opioid Peptides Identified From Two Synthetic Combinatorial Libraries Peptide Research 8(3):124-137 (1995).
He, et al., Dynorphina—(2-17) Restores Spinal/Supraspinal Morphine Synergy in Morphine-Tolerant MICE1, Geraldine Brush Cance research Inst., Calif. Pac. Med. Ctr. Res. Ins., The J. of Pharm. & Experimental Therapeutics, 280:1210-1214 (1997).
Kieffer, et al. 32P-Labeled Opioid Peptides With High Affinity for the —Opioid Receptor Ecole Superieure de Biotechnologies, 1-8 (1993).
Krantz, A., Red Cell-Mediated Therapy: Opportunities and Challenges, Blood Cells, Molecules and Diseases 23(3):58-68 (1997).
Isom, G. E., Production and Characterization of Anti-Morphine Anti-Idiotypic Antibodies, Methodolgical Survey in Biochemistry and Analysis, 15:109-14 (1985).
Anand, et al., The Rat Brain Delta Opioid Receptor Studies with Anti-Idiotypic Antibodies to Anti-Leucine Enkephalin, Indiana Journal of Biochemistry & Biophysics, 30:117-122 (Apr. 93).
Cuello, et al., Characterization and Immunocytochemical Application of Monoclonal Antibodies Against Enkephalins, J. of Histochemistry and Cytochemistry, 32:(9)947-57 (1984).
Watkins, et al., Presence of B-Endorphin-Like Immunoreactivity in the Anterior Pituitary Gland of Rat and Man and Evidence for the Differential Localization with ACTH, Cell Tissue Res. 215 (3):577-89 (1981).
Borvendeg, et al., Radioimmunoassay of B-Endorphin: Immunoreactive Substances in the Brain and the Pituitary, Endorphins ′78, Int'l Workshop Conf. Budapest, Hungary, Oct. 2-6, 1978, pp. 177-186 (1978).
Weissman, et al., Specific Antiserum to Leu-Enkephalin and its Use in a Radioimmunoassay, FEBS Letters, 70:(1)245-8 (1976).
Bridon Dominique P.
Ezrin Alan M.
Holmes Darren L.
Milner Peter G.
Conjuchem, Inc.
Low Christopher S. F.
Lukton David
LandOfFree
Conjugates of opioids and endogenous carriers does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Conjugates of opioids and endogenous carriers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Conjugates of opioids and endogenous carriers will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2940342